Trends in Sodium–Glucose Cotransporter 2 Inhibitor and Glucagon‑Like Peptide‑1 Receptor Agonist Prescription Rates Among Patients With Type 2 Diabetes: An Epic Cosmos Real-World Data Analysis, 2014-2024
Trends in Sodium–Glucose Cotransporter 2 Inhibitor and Glucagon‑Like Peptide‑1 Receptor Agonist Prescription Rates Among Patients With Type 2 Diabetes: An Epic Cosmos Real-World Data Analysis, 2014-2024. // AACE Endocrinology and Diabetes. – URL: https://www.sciencedirect.com/science/article/pii/S305091572600072X?dgcid=rss_sd_all
Trends in Sodium–Glucose Cotransporter 2 Inhibitor and Glucagon‑Like Peptide‑1 Receptor Agonist Prescription Rates Among Patients With Type 2 Diabetes: An Epic Cosmos Real-World Data Analysis, 2014-2024. AACE Endocrinology and Diabetes. https://www.sciencedirect.com/science/article/pii/S305091572600072X?dgcid=rss_sd_all
“Trends in Sodium–Glucose Cotransporter 2 Inhibitor and Glucagon‑Like Peptide‑1 Receptor Agonist Prescription Rates Among Patients With Type 2 Diabetes: An Epic Cosmos Real-World Data Analysis, 2014-2024.” AACE Endocrinology and Diabetes.
@article{article106989,
title = {Trends in Sodium–Glucose Cotransporter 2 Inhibitor and Glucagon‑Like Peptide‑1 Receptor Agonist Prescription Rates Among Patients With Type 2 Diabetes: An Epic Cosmos Real-World Data Analysis, 2014-2024},
journal = {AACE Endocrinology and Diabetes},
url = {https://www.sciencedirect.com/science/article/pii/S305091572600072X?dgcid=rss_sd_all}
}